Crane Ryan, Conley Shannon M, Al-Ubaidi Muayyad R, Naash Muna I
Department of Biomedical Engineering, University of Houston, Houston, TX, United States.
Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Front Neurosci. 2021 Mar 17;15:652215. doi: 10.3389/fnins.2021.652215. eCollection 2021.
Vision and hearing disorders comprise the most common sensory disorders found in people. Many forms of vision and hearing loss are inherited and current treatments only provide patients with temporary or partial relief. As a result, developing genetic therapies for any of the several hundred known causative genes underlying inherited retinal and cochlear disorders has been of great interest. Recent exciting advances in gene therapy have shown promise for the clinical treatment of inherited retinal diseases, and while clinical gene therapies for cochlear disease are not yet available, research in the last several years has resulted in significant advancement in preclinical development for gene delivery to the cochlea. Furthermore, the development of somatic targeted genome editing using CRISPR/Cas9 has brought new possibilities for the treatment of dominant or gain-of-function disease. Here we discuss the current state of gene therapy for inherited diseases of the retina and cochlea with an eye toward areas that still need additional development.
视觉和听觉障碍是人类最常见的感觉障碍。许多形式的视力和听力丧失是遗传性的,目前的治疗方法只能为患者提供暂时或部分缓解。因此,针对数百种已知的导致遗传性视网膜和耳蜗疾病的致病基因开发基因疗法一直备受关注。基因治疗领域最近令人兴奋的进展已显示出对遗传性视网膜疾病进行临床治疗的前景,虽然针对耳蜗疾病的临床基因疗法尚未问世,但过去几年的研究已使将基因递送至耳蜗的临床前开发取得了重大进展。此外,使用CRISPR/Cas9进行体细胞靶向基因组编辑的发展为治疗显性或功能获得性疾病带来了新的可能性。在此,我们着眼于仍需进一步发展的领域,讨论视网膜和耳蜗遗传性疾病的基因治疗现状。